Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Denmark: Novo Nordisk has announced that Lars Fruergaard Jorgensen will step down from his role as CEO of Novo Nordisk. He ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 million Danish ...